Opinion|Videos|August 8, 2024
Evolving Goals in Rheumatoid Arthritis Treatment: Defining and Achieving Clinical Remission
A panel of medical experts discuss how clinical guidelines currently define clinical remission, as well as the clinical and economic benefits associated with clinical remission.
Advertisement
Episodes in this series
Over the past few years, the goal of rheumatoid arthritis treatment has evolved from relieving symptoms to achieving clinical remission, which inhibits radiologic damage and prevents disability.
1. How do clinical guidelines currently define clinical remission?
2. What are the clinical and economic benefits associated with clinical remission?
Advertisement
Related to this article
The EC approved upadacitinib for active polyarticular JIA in children 2 years and older, based on phase 1 SELECT-YOUTH efficacy and safety data.
August 2026 rheumatology highlights include FDA approval of brepocitinib for dermatomyositis and garetosmab-grts for FOP, and new trial data.
In RA-BRIDGE and RA-BRANCH, baricitinib failed to demonstrate VTE noninferiority in patients with RA enriched for thromboembolic risk factors.
A Phase 2a basket trial produced ACR50 responses in 71% of refractory RA patients at 6 months.
Advertisement
Advertisement